Read the latest press releases from Leios Therapeutics.
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
La Jolla, California, January 26, 2026 — Leios Therapeutics, a clinical-stage biotechnology company focused on innovative aesthetic therapies, today announced the execution of a licensing agreement for 10XB-101, its investigational product for focal fat reduction and body contouring, along with a strategic equity investment by BNC Korea (KOSDAQ:256840), a leading healthcare and aesthetics-focused company in South Korea.
10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring
SAN DIEGO – August 16, 2023 – 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today that it has completed enrollment in a repeat treatment study of its novel injectable drug for submental body contouring.
10xBio Announces the Completion of Enrollment In Phase 2b Clinical Trial of Novel Drug For Submental Body Contouring
10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today that it has completed enrollment in a repeat treatment study of its novel injectable drug for submental body contouring.
10xBio Provides Update on Patent Portfolio
SAN DIEGO (July 15, 2023) – 10xBio, LLC, a privately-held biotechnology company, announces that in the past 24 months it has been issued 3 patents from the U.S. Patent…
10xBio Completes Series B Financing
SAN DIEGO (August 23, 2021) – 10xBio, LLC, a privately-held biotechnology company, completed a Series B financing from a select group of partners and private investors.
Hugel Acquires Phase 2 U.S. Clinical Data to 10XB101 and Exercises China Option for the Drug Product
SAN DIEGO (August 12, 2021) – 10xBio, LLC, a privately-held biotechnology company, announces that its Korean Partner, Hugel…
10xBio Announces the Completion of Phase 2 Clinical Trial of 10XB101
SAN DIEGO (August 3, 2021) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has completed a Phase 2 dose escalation study of its novel injectable drug product for body contouring.
10xBio Announces the Completion of Phase 1B Clinical Trial of 10XB101
SAN DIEGO (May 6, 2019) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has completed a Phase 1B study of its novel injectable drug product for body contouring.
10xBio Announces the Acceptance of a U.S. IND for the Initiation of Clinical Trials of 10XB101
SAN DIEGO (April 2, 2018) – 10xBio, LLC, a privately-held biotechnology company, announced today that the Investigational New Drug “IND” application for 10XB101 has been accepted by the U.S. FDA.
10xBio Completes Series A Financing
SAN DIEGO (April 2, 2018) – 10xBio, LLC, a privately-held biotechnology company, completed a Series A financing from a select group of partners and private investors during the first quarter of 2018.
10xBio Announces Issuance of U.S. Patent
SAN DIEGO (May 31, 2017) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has been issued patent 9,351,945 from the U.S. Patent and Trademark Office.